- Home
- MGNX vs DMA Comparison
MGNX vs DMA Comparison
Compare MGNX & DMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- DMA
- Stock Information
- Founded
- MGNX 2000
- DMA 2011
- Country
- MGNX United States
- DMA United States
- Employees
- MGNX N/A
- DMA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- DMA Trusts Except Educational Religious and Charitable
- Sector
- MGNX Health Care
- DMA Finance
- Exchange
- MGNX Nasdaq
- DMA Nasdaq
- Market Cap
- MGNX 70.3M
- DMA 72.0M
- IPO Year
- MGNX 2013
- DMA N/A
- Fundamental
- Price
- MGNX $1.43
- DMA $8.40
- Analyst Decision
- MGNX Hold
- DMA
- Analyst Count
- MGNX 10
- DMA 0
- Target Price
- MGNX $6.83
- DMA N/A
- AVG Volume (30 Days)
- MGNX 599.1K
- DMA 34.6K
- Earning Date
- MGNX 05-20-2025
- DMA 01-01-0001
- Dividend Yield
- MGNX N/A
- DMA 2.04%
- EPS Growth
- MGNX N/A
- DMA N/A
- EPS
- MGNX N/A
- DMA N/A
- Revenue
- MGNX $149,962,000.00
- DMA N/A
- Revenue This Year
- MGNX N/A
- DMA N/A
- Revenue Next Year
- MGNX $80.86
- DMA N/A
- P/E Ratio
- MGNX N/A
- DMA N/A
- Revenue Growth
- MGNX 155.26
- DMA N/A
- 52 Week Low
- MGNX $0.99
- DMA $4.78
- 52 Week High
- MGNX $14.91
- DMA $8.00
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- DMA 54.92
- Support Level
- MGNX $1.54
- DMA $8.25
- Resistance Level
- MGNX $1.82
- DMA $8.54
- Average True Range (ATR)
- MGNX 0.15
- DMA 0.19
- MACD
- MGNX 0.01
- DMA 0.04
- Stochastic Oscillator
- MGNX 19.79
- DMA 70.97
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.